Therapeutics Enter Oncology Articles & Analysis
6 articles found
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods. Alfa Cytology, which stands at the forefront of oncology service provision in New York United States, has announced its sophisticated antibody-drug conjugates(ADCs) development services for cancer. The pioneering ...
Alfa Cytology introduces comprehensive small molecule PARPi development services for combating various diseases. Alfa Cytology, a developer of oncology innovation, has announced its latest venture small molecule Poly(ADP-ribose) polymerase inhibitor development services. This cutting-edge initiative represents a major advancement in creating more precise and versatile cancer treatment ...
The contemporary sphere of oncological therapeutics has witnessed a phenomenal shift in methodology, pivoting from conventional treatment modalities to exploring and utilizing the power of biological entities, notably viruses. Oncolytic virotherapy stands as an avant-garde dissertation in this evolution. It is predicated on the judicious fabrication of Oncolytic Viruses (OVs), biological entities ...
Navigating Cancer announced today that Alexandra Snyder, MD, Chief Medical Officer at Generate Biomedicines, has agreed to join its board of directors. Dr. Snyder is succeeding David M. Rubin, Ph.D. who served on Navigating Cancer’s Board from 2015 to the present. “We are pleased to welcome Dr. Snyder to Navigating Cancer’s Board and especially value her point of view as a ...
Introducing Beacon Biosignals: a neurotechnology company founded to develop machine learning-enabled EEG neurobiomarkers and accelerate precision medicine for any disease state affecting the brain Founded by MD/PhDs and engineers from Harvard and MIT, Beacon is propelled by the vision of a computing platform designed to scale the interrogation of large brain datasets with unprecedented ...
We've added over 125 new datasets to our Cancer Model Database. It provides access to a comprehensive collection of well-established tumor models for early-stage oncology research and increases their translational capabilities to the clinic. The update adds new patient-derived xenograft (PDX) models for several cancer types, including anal, colon, kidney, renal, and leukemia. Additionally, this ...